keyword
https://read.qxmd.com/read/38569809/a-cross-sectional-survey-study-of-cannabis-use-for-fibromyalgia-symptom-management
#1
JOURNAL ARTICLE
Abhinav Singla, Christopher V Anstine, Linda Huang, Jordan K Rosedahl, Arya B Mohabbat, Lindsey M Philpot
OBJECTIVE: To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia. PATIENTS AND METHODS: An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia...
April 2024: Mayo Clinic Proceedings
https://read.qxmd.com/read/38569807/is-medical-cannabis-a-solution-for-controlling-fibromyalgia-symptoms
#2
EDITORIAL
Paula David, Aia Mohsen, Howard Amital
No abstract text is available yet for this article.
April 2024: Mayo Clinic Proceedings
https://read.qxmd.com/read/38496341/scoping-review-the-role-of-psychedelics-in-the-management-of-chronic-pain
#3
REVIEW
Christopher L Robinson, Alexandra C G Fonseca, Efemena M Diejomaoh, Ryan S D'Souza, Michael E Schatman, Vwaire Orhurhu, Trent Emerick
INTRODUCTION: Amid a lack of effective chronic pain treatments, psychedelics have gained attention as a potential solution, although their Schedule 1 classification poses challenges. Psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, have gained popularity as alternatives and adjuncts for chronic pain treatment. Studies suggest that they may modulate pain processing through agonism primarily at the serotonin receptor, 5-HT2A . One of the first of its nature, we present an artificial intelligence (AI)-powered scoping review primarily focusing on evaluating psychedelics for chronic pain conditions such as cluster headache, phantom limb pain, and fibromyalgia...
2024: Journal of Pain Research
https://read.qxmd.com/read/38025837/pain-medications-used-by-persons-living-with-fibromyalgia-a-comparison-between-the-profile-of-a-quebec-sample-and-clinical-practice-guidelines
#4
JOURNAL ARTICLE
Gwenaelle De Clifford-Faugère, Hermine Lore Nguena Nguefack, Marimée Godbout-Parent, Mamadou Aliou Diallo, Line Guénette, M Gabrielle Pagé, Manon Choinière, Sylvie Beaudoin, Aline Boulanger, Anne Marie Pinard, David Lussier, Philippe De Grandpré, Simon Deslauriers, Anaïs Lacasse
BACKGROUND: Pharmacological management of fibromyalgia is complex. Chronic pain management is characterized by off-label prescribing and use, multimorbidity, and polypharmacy. AIMS: This study aimed to describe pain medications use and perceived risk among people living with fibromyalgia and compare this use to evidence-based recommendations. METHODS: Directive telephone interviews were conducted with 63 individuals self-reporting a diagnosis of fibromyalgia (Quebec, Canada)...
2023: Canadian Journal of Pain, Revue Canadienne de la Douleur
https://read.qxmd.com/read/37917863/cannabis-and-rheumatoid-arthritis-a-scoping-review-evaluating-the-benefits-risks-and-future-research-directions
#5
REVIEW
Nicole Paland, Haya Hamza, Antonina Pechkovsky, Miran Aswad, Dayana Shagidov, Igal Louria-Hayon
Rheumatoid diseases, including rheumatoid arthritis, osteoarthritis, and fibromyalgia, are characterized by progressive inflammation in the musculoskeletal system, predominantly affecting the joints and leading to cartilage and bone damage. The resulting pain and ongoing degradation of the musculoskeletal system contribute to reduced physical activity, ultimately impacting quality of life and imposing a substantial socioeconomic burden. Unfortunately, current therapeutics have limited efficacy in slowing disease progression and managing pain...
October 29, 2023: Rambam Maimonides Medical Journal
https://read.qxmd.com/read/37903591/successful-treatment-of-a-fibromyalgia-patient-using-a-homeopathic-preparation-of-cannabis-sativa
#6
JOURNAL ARTICLE
Jozélio Freire de Carvalho, Maria Fernanda Leal Dos Santos Ribeiro
BACKGROUND:  Homeopathy has been used in observational and controlled studies to treat patients with fibromyalgia (FM), but none has previously used the remedy Cannabis sativa . CASE HISTORY:  A 51-year-old female patient presenting with diffuse pain and sleep disorder was diagnosed with FM using the relevant American College of Rheumatology criteria. She reported having 18 tender points, a pain score (visual analog scale, VAS) of 9.0, and a well-being VAS of 5...
October 30, 2023: Homeopathy: the Journal of the Faculty of Homeopathy
https://read.qxmd.com/read/37823303/relationship-between-nociplastic-pain-involvement-and-medication-use-symptom-relief-and-adverse-effects-among-people-using-medical-cannabis-for-chronic-pain
#7
JOURNAL ARTICLE
J Ryan Scott, David A Williams, Steven E Harte, Richard E Harris, Evangelos Litinas, Suzanne Sisley, Daniel J Clauw, Kevin F Boehnke
OBJECTIVES: Cannabis is increasingly being used for chronic pain management, but cannabis' effects remain poorly characterized in chronic nociplastic pain (NPP), which is posited to be caused by disturbances in nervous system pain processing. In this cross-sectional study (n=1213), we used the 2011 Fibromyalgia (FM) Survey Criteria as a surrogate measure for degree of NPP among individuals using medical cannabis for chronic pain. METHODS: Using a quartile-split, we investigated associations between the degree of NPP and medication use, cannabis use characteristics, and symptom relief...
January 1, 2024: Clinical Journal of Pain
https://read.qxmd.com/read/37384372/evaluating-the-supporting-evidence-of-medical-cannabis-claims-made-on-clinic-websites-cross-sectional-study
#8
JOURNAL ARTICLE
Braden O'Neill, Jacob Ferguson, Lauren Dalueg, Abban Yusuf, Abirami Kirubarajan, Taryn Lloyd, Eisi Mollanji, Navindra Persaud
BACKGROUND: Since the legalization of medical cannabis in Canada in 2013, prescription of cannabis for medical purposes has become commonplace and a multibillion dollar industry has formed. Much of the media coverage surrounding medical cannabis has been positive in nature, leading to Canadians potentially underestimating the adverse effects of medical cannabis use. In recent years, there has been a large increase in clinic websites advertising the use of medical cannabis for health indications...
June 29, 2023: Journal of Medical Internet Research
https://read.qxmd.com/read/37371716/cannabis-for-the-treatment-of-fibromyalgia-a-systematic-review
#9
REVIEW
Natalie H Strand, Jillian Maloney, Molly Kraus, Christopher Wie, Michal Turkiewicz, Diego A Gomez, Olufunmilola Adeleye, Monica W Harbell
Fibromyalgia is a common disease syndrome characterized by chronic pain and fatigue in conjunction with cognitive dysfunction such as memory difficulties. Patients currently face a difficult prognosis with limited treatment options and a diminished quality of life. Given its widespread use and potential efficacy in treating other types of pain, cannabis may prove to be an effective treatment for fibromyalgia. This review aims to examine and discuss current clinical evidence regarding the use of cannabis for the treatment of fibromyalgia...
June 2, 2023: Biomedicines
https://read.qxmd.com/read/37289246/-tetrahydrocannabinol-thc-in-patients-with-fibromyalgia-syndrome-fms-a-retrospective-study-of-changes-in-pain-psychometric-variables-and-analgesic-consumption-during-inpatient-interdisciplinary-multimodal-pain-therapy-impt
#10
JOURNAL ARTICLE
Horst Bettstetter, Arne Schäfer
BACKGROUND: Since March 1, 2017, medical cannabis (MC) can be prescribed nationwide in Germany. To date, there have been a number of qualitatively different studies on the effectiveness of MC in fibromyalgia syndrome (FMS). OBJECTIVE: The aim of the study was to investigate the effectiveness of THC in the course of interdisciplinary multimodal pain therapy (IMPT) on pain and several psychometric variables. MATERIALS AND METHODS: For the study, in the period 2017-2018, all patients in the pain ward of a clinic who were suffering from FMS and were treated in a multimodal interdisciplinary setting were selected based on inclusion criteria...
June 8, 2023: Der Schmerz
https://read.qxmd.com/read/37243707/temporal-associations-between-use-of-psychoactive-substances-and-somatic-symptoms-in-the-daily-lives-of-people-with-fibromyalgia
#11
JOURNAL ARTICLE
Duygu Kuzu, Thomas R Valentine, Anna L Kratz
OBJECTIVE: Consumption of psychoactive substances-alcohol, nicotine, caffeine, opioids, and cannabis-is common among people with fibromyalgia (FM). Associations between the use of substances and somatic symptoms could reflect efforts to cope with symptoms, aggravation or alleviation of symptoms following the use of substances, or a combination of these. To date, no study has provided insight into temporal associations between the consumption of psychoactive substances and fluctuations in somatic symptoms...
May 27, 2023: Pain Medicine
https://read.qxmd.com/read/37199833/assessment-of-clinical-outcomes-in-patients-with-fibromyalgia-analysis-from-the-uk-medical-cannabis-registry
#12
JOURNAL ARTICLE
Claire Wang, Simon Erridge, Carl Holvey, Ross Coomber, Azfer Usmani, Mohammed Sajad, Rahul Guru, Wendy Holden, James J Rucker, Michael W Platt, Mikael H Sodergren
INTRODUCTION: There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health-related quality of life and incidence of adverse events of those prescribed cannabis-based medicinal products (CBMPs) for fibromyalgia. METHODS: Patients treated with CBMPs for a minimum of 1 month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient-reported outcome measures (PROMs)...
May 18, 2023: Brain and Behavior
https://read.qxmd.com/read/36971587/clinical-practice-guidelines-for-cannabis-and-cannabinoid-based-medicines-in-the-management-of-chronic-pain-and-co-occurring-conditions
#13
JOURNAL ARTICLE
Alan D Bell, Caroline MacCallum, Shari Margolese, Zach Walsh, Patrick Wright, Paul J Daeninck, Enrico Mandarino, Gary Lacasse, Jagpaul Kaur Deol, Lauren de Freitas, Michelle St Pierre, Lynne Belle-Isle, Marilou Gagnon, Sian Bevan, Tatiana Sanchez, Stephanie Arlt, Max Monahan-Ellison, James O'Hara, Michael Boivin, Cecilia Costiniuk
Background: One in five individuals live with chronic pain globally, which often co-occurs with sleep problems, anxiety, depression, and substance use disorders. Although these conditions are commonly managed with cannabinoid-based medicines (CBM), health care providers report lack of information on the risks, benefits, and appropriate use of CBM for therapeutic purposes. Aims: We present these clinical practice guidelines to help clinicians and patients navigate appropriate CBM use in the management of chronic pain and co-occurring conditions...
March 27, 2023: Cannabis and Cannabinoid Research
https://read.qxmd.com/read/36751980/cannabis-for-treating-fibromyalgia
#14
JOURNAL ARTICLE
Alaa Abd-Elsayed, Christopher Gilligan
No abstract text is available yet for this article.
February 8, 2023: Pain Practice: the Official Journal of World Institute of Pain
https://read.qxmd.com/read/36707893/cannabis-opioid-interaction-in-the-treatment-of-fibromyalgia-pain-an-open-label-proof-of-concept-study-with-randomization-between-treatment-groups-cannabis-oxycodone-or-cannabis-oxycodone-combination-the-spiral-study
#15
RANDOMIZED CONTROLLED TRIAL
Cornelis Jan van Dam, Monique van Velzen, Cornelis Kramers, Arnt Schellekens, Erik Olofsen, Marieke Niesters, Albert Dahan
BACKGROUND: Opioids continue to be widely prescribed for chronic noncancer pain, despite the awareness that opioids provide only short-time pain relief, lead to dose accumulation, have numerous adverse effects, and are difficult to wean. As an alternative, we previously showed advantages of using pharmaceutical-grade cannabis in a population of chronic pain patients with fibromyalgia. It remains unknown whether combining an opioid with pharmaceutical-grade cannabis has advantages, such as fewer side effects from lesser opioid consumption in chronic pain...
January 27, 2023: Trials
https://read.qxmd.com/read/36639601/cannabinoids-as-a-potential-alternative-to-opioids-in-the-management-of-various-pain-subtypes-benefits-limitations-and-risks
#16
REVIEW
Samuel P Ang, Shawn Sidharthan, Wilson Lai, Nasir Hussain, Kiran V Patel, Amitabh Gulati, Onyeaka Henry, Alan D Kaye, Vwaire Orhurhu
INTRODUCTION: Pain is a global phenomenon encompassing many subtypes that include neuropathic, musculoskeletal, acute postoperative, cancer, and geriatric pain. Traditionally, opioids have been a mainstay pharmacological agent for managing many types of pain. However, opioids have been a subject of controversy with increased addiction, fatality rates, and cost burden on the US healthcare system. Cannabinoids have emerged as a potentially favorable alternative or adjunctive treatment for various types of acute and chronic pain...
January 13, 2023: Pain and Therapy
https://read.qxmd.com/read/36381652/plasma-and-interstitial-levels-of-endocannabinoids-and-n-acylethanolamines-in-patients-with-chronic-widespread-pain-and-fibromyalgia-a-systematic-review-and-meta-analysis
#17
REVIEW
Inna Kurlyandchik, Romy Lauche, Evelin Tiralongo, Leon N Warne, Janet Schloss
The endocannabinoid system (ECS) is an essential endogenous signaling system that may be involved in the pathophysiology of chronic widespread pain (CWP) and fibromyalgia syndrome (FMS). Further research is required to understand the role of ECS in the development and maintenance of CWP and FMS. We provided the first systematic review and meta-analysis exploring the clinical relevance of ECS alterations in patients with CWP and FMS by comparing plasma and interstitial levels of endocannabinoids and N-acylethanolamines in patients and healthy controls...
2022: Pain Reports
https://read.qxmd.com/read/36333278/the-role-of-cannabis-in-treatment-resistant-fibromyalgia-women
#18
JOURNAL ARTICLE
Oded Hershkovich, Yemima Hayun, Nataly Oscar, Arnold Shtein, Raphael Lotan
BACKGROUND: Fibromyalgia is a complex pain-focused syndrome. Previous studies showed that Cannabis is efficacious in promoting sleep, deepening and lengthening the sleep cycle, and good pain relief (compared with the SSRIs and SNRIs). PURPOSE: This study aimed to use the World Health Organization Quality of Life Bref questionnaire (WhoQoL-bref) to characterize the impact of Cannabis Treatment initiation on the quality of life in women suffering from treatment-resistant fibromyalgia...
November 4, 2022: Pain Practice: the Official Journal of World Institute of Pain
https://read.qxmd.com/read/36129666/systematic-review-and-meta-analysis-seem-to-indicate-that-cannabinoids-for-chronic-primary-pain-treatment-have-limited-benefit
#19
JOURNAL ARTICLE
Riccardo Giossi, Federica Carrara, Matteo Padroni, Maria Concetta Bilancio, Martina Mazzari, Silvia Enisci, Maria Silvia Romio, Gloria Boni, Federica Corrù, Veronica Andrea Fittipaldo, Irene Tramacere, Arianna Pani, Francesco Scaglione, Diego Fornasari
INTRODUCTION: The IASP ICD-11 chronic primary pain (CPP) definition includes 19 different painful conditions. In recent years, interest in the potential role of cannabinoids in the management of CPP has increased, since they demonstrated a possible efficacy in treating pain, especially in secondary pain conditions. However, limited evidence is available for patients with CPP. The aim of this systematic review and meta-analysis is to evaluate the efficacy and safety of cannabinoid administration in CPP...
September 21, 2022: Pain and Therapy
https://read.qxmd.com/read/35988425/broad-spectrum-cannabis-oil-ameliorates-reserpine-induced-fibromyalgia-model-in-mice
#20
JOURNAL ARTICLE
Eduarda Gomes Ferrarini, Rodrigo Sebben Paes, Gabriela Mantovani Baldasso, Pollyana Mendonça de Assis, Murilo Chaves Gouvêa, Paola De Cicco, Nádia Rezende Barbosa Raposo, Raffaele Capasso, Eduardo Luiz Gasnhar Moreira, Rafael Cypriano Dutra
Fibromyalgia (FM) is an idiopathic disorder characterized by generalized pain and associated symptoms such as depression and anxiety. Cannabis sativa shows different pharmacological activities, such as analgesic, anti-inflammatory, neuroprotective, and immunomodulatory. Associated with this, the use of an oil with low concentrations of THC can reduce the psychomimetic adverse effects of the plant. Therefore, the present study aimed to evaluate the analgesic effect of broad-spectrum cannabis oil with low THC concentration in an experimental model of FM...
October 2022: Biomedicine & Pharmacotherapy
keyword
keyword
165026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.